Hepatology
Post-transplant biliary complications: advances in pathophysiology, diagnosis, and treatment
3 Feb, 2023 | 14:01h | UTC
Cohort Study | Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis
24 Jan, 2023 | 14:14h | UTC
Cross-sectional study | Non-heavy alcohol use associated with liver fibrosis and ‘nonalcoholic’ steatohepatitis
20 Jan, 2023 | 14:29h | UTCNon-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study – Clinical Gastroenterology and Hepatology (link to abstract – $ for full-text)
Commentary: Study finds non-heavy alcohol use associated with liver fibrosis – Boston University School of Medicine
AGA clinical practice update on diagnosis and management of acute hepatic porphyrias
17 Jan, 2023 | 13:19h | UTC
Review | Liver intensive care for the general intensivist
17 Jan, 2023 | 12:59h | UTCLiver intensive care for the general intensivist – Anaesthesia
Development and validation of a prognostic nomogram for older patients with acute-on-chronic liver diseases
15 Jan, 2023 | 19:46h | UTCSee also: dynamic nomogram
Review | The pathogenesis and therapeutic strategies of heat stroke-induced liver injury
13 Jan, 2023 | 13:07h | UTCThe pathogenesis and therapeutic strategies of heat stroke-induced liver injury – Critical Care
Review | Early diagnosis and prevention of infections in cirrhosis
12 Jan, 2023 | 12:47h | UTCEarly Diagnosis and Prevention of Infections in Cirrhosis – Seminars in Liver Disease
Review | Management of acute kidney injury in patients with cirrhosis.
5 Dec, 2022 | 00:11h | UTCManagement of AKI in Patients with Cirrhosis – Current Treatment Options in Gastroenterology
RCT | Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis.
2 Dec, 2022 | 14:24h | UTCRivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis – NEJM Evidence
Commentary on Twitter
This #RCT examined the use of rivaroxaban to reduce risk of venous thromboembolism (VTE) in pts with non-cirrhotic chronic portal vein thrombosis (PVT). Daily rivaroxaban reduced incidence of VTE and did not increase major bleeding events. https://t.co/CbenUb8ZWz#LiverTwitter pic.twitter.com/bgN1QS171j
— NEJM Evidence (@NEJMEvidence) November 22, 2022
Review | Public health measures and prevention of alcohol-associated liver disease.
27 Nov, 2022 | 22:14h | UTC
Commentary from one of the authors on Twitter
Public Health Measures and Prevention of Alcohol-Associated Liver Disease @JCEH_Hepatology @LuisAntonioDiaz @FcoIdalsoaga @CokeArnold1 #LiverTwitter https://t.co/8pVLg5Kffp pic.twitter.com/OCrIYgVhJa
— Juan Pablo (JP) Arab, MD (@juanpabloarab) June 28, 2022
KDIGO 2022 Guideline for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.
23 Nov, 2022 | 14:11h | UTCExecutive Summary: KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease – Kidney International
Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure.
21 Nov, 2022 | 14:21h | UTC
Portopulmonary hypertension: current developments and future perspectives.
21 Nov, 2022 | 14:20h | UTCPortopulmonary hypertension: Current developments and future perspectives – Liver Research
Related: Pulmonary complications in liver disease – Intensive Care Medicine (free)
Related Reviews:
Pulmonary complications of hepatic diseases – World Journal of Gastroenterology
Phase 2b RCT | Efficacy and safety of Bepirovirsen in chronic Hepatitis B infection.
11 Nov, 2022 | 13:44h | UTCEfficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hep B virus (HBV) messenger RNAs, resulted in sustained loss of hep B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection. #TLM22 #LiverTwitter https://t.co/krJcMEDhIX pic.twitter.com/SistuAocZO
— NEJM (@NEJM) November 8, 2022
Retrospective Cohort Study | Perinatal outcomes associated with ICP in twin pregnancies were worse than singletons.
11 Nov, 2022 | 13:36h | UTC
M-A | Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis.
8 Nov, 2022 | 11:58h | UTC
Review | Determining prognosis of alcoholic liver disease and alcoholic hepatitis.
4 Nov, 2022 | 13:17h | UTC
ERAS Guidelines for perioperative care for liver surgery.
1 Nov, 2022 | 12:16h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Review | Management of NAFLD in primary care settings.
27 Oct, 2022 | 12:24h | UTCManagement of NAFLD in primary care settings – Liver International
Related:
Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports
Commentary on Twitter
Opportunities of assessment and treatment of #NAFLD in primary care settings
✍️ @VWSWong @DrJavierCrespo @JVLazarus #livertwitter #liverreviews #NASH pic.twitter.com/5SLqNvafAm
— Liver International (@LiverInt) October 23, 2022
AHA Scientific Statement | Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates.
24 Oct, 2022 | 14:11h | UTCTop Things to Know: Emerging Evidence on Coronary Heart Disease (CHD) Screening in Kidney and Liver Transplantation Candidates – American Heart Association
Case-control study | Post-paracentesis ascitic fluid leak in patients with cirrhosis of liver and its management.
21 Oct, 2022 | 12:57h | UTC
M-A of RCT | Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis.
20 Oct, 2022 | 12:25h | UTCCarvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis – Journal of Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
#Carvedilol
➡️non-selective #βblocker
✅associated with reduced risk of decompensating events
➡️improved survival in patients with #cirrhosis & #portalhypertensionRead it here👉https://t.co/yy8DIJBhfL#LiverTwitter pic.twitter.com/XxmrB7gff8
— Journal of Hepatology (@JHepatology) October 13, 2022
Choosing Wisely | Top five list of procedures to avoid in the treatment of viral hepatitis.
7 Oct, 2022 | 14:22h | UTCSee complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
Baveno VII – Renewing consensus in portal hypertension.
7 Oct, 2022 | 14:17h | UTCBaveno VII – Renewing consensus in portal hypertension – Journal of Hepatology